Table 2.
Study characteristics of prospective studies.
| Author and (Year) | Study Design | Data Collection Period | Study Location | Patients Included in Intervention Group(s) (n) | Mean Age | Intervention | Control/Comparator |
|---|---|---|---|---|---|---|---|
| Bagla (2014) [27] | prospective | Jan 2012–Mar 2013 | United States | 19 | 66.5 | PAE with 100–400 µm Embozene® | |
| Bilhim (2013) [29] | prospective | Mar 2009–Dec 2011 | Portugal | 122 | 65.8 bilateral PAE; 71.3 unilateral PAE | PAE with 100- and 200 µm particle sizes, unilateral vs. bilateral | |
| Brown (2018) [30] | prospective | Nov 2015–Feb 2017 | Australia | 51 | 67 | PAE with 250 µm Embozene® | |
| Carnevale (2013) [31] | prospective | Jun 2008–Nov 2011 | Brazil | 11 | 68.5 | PAE with 300–500 µm Embosphere® | |
| Franiel (2018) [32] | prospective | Jul 2014–Dec 2015 | Germany | 27 | 66 | PAE with 250 µm Embozene® | |
| Goncalves (2016) [33] | prospective | Aug 2011–Jun 2013 | Brazil | 30 | not mentioned | PAE with 100–300 or 300–500 µm Embosphere® | |
| Kenny (2019) [34] | prospective | Not mentioned | France | 20 | 75.3 | PAE with 300–500 µm Bead Block® in patients with indwelling catheters | |
| Kløw (2018) [35] | prospective | Dec 2015–Mar 2017 | Norway | 29 | 69 | PAE with 300–500 µm Embosphere® | |
| Kurbatov (2014) [18] | prospective | Jan 2009–Jan 2012 | Russia and Italy | 88 | 66.4 | PAE with 300–500 µm Embosphere® in prostates >80 cm3 | |
| Lindgren (2019) [36] | prospective | Jan 2015–Jun 2018 | Sweden | 37 | 73 | PAE with 300–500 µm Embosphere® | |
| Malling (2019) [21] | prospective | Jul 2017–Jul 2018 | Denmark | 11 | 75.2 | PAE PErFecTED with 300–500 µm Embosphere® | |
| Rampoldi (2017) [19] | prospective | Not mentioned | Italy | 41 | 77.9 | PAE PErFecTED with 300–500 µm Embosphere® in patients with indwelling catheters | Indwelling urinary catheter |
| Ray (2018) [39] | prospective | Jul 2014–Jan 2016 | United Kingdom | 199 | 66 | PAE | TURP |
| Russo (2015) [40] | prospective matched pair | Jan 2006–Jan 2014 | Italy | 80 | 67 | PAE with 300–500 µm Embosphere® | open prostatectomy |
| Salem (2018) [41] | prospective | Dec 2014–Jun 2017 | United States | 45 | 67 | PAE with 300–500 µm Embosphere® | |
| Wang (2016) [43] | prospective | Apr 2010–Dec 2013 | China | 115 | 72.5 (>80 cm3); 66 (50–80 cm3) | PAE with 100 µm particles in prostates >80 cm3 and 50–80 cm3 | |
| Wang (2016) [44] | prospective | Feb 2009–Apr 2014 | China | 158 | 82.5 (>75 yrs), 67.5 (<75 yrs) | PAE with 100 µm particles in men >75 years and <75 years | |
| Yu (2016) [45] | prospective | Jun 2015–Mar 2016 | Hong Kong SAR | 16 | 66 | PAE with 100–300 µm Embosphere® in patients with BPH and acute urinary retention | PAE with 100–300 µm Embosphere® n patients with BPH without urinary retention |
| Yu (2019) [46] | prospective | Jun 2015–Dec 2018 | Hong Kong SAR | 82 | 66 | PAE with 100–300 µm Embosphere® |
BPH, benign prostatic hyperplasia; PAE, prostatic artery embolization; PErFecTED, proximal embolization first then embolize distant; TURP, transurethral resection of the prostate.